Ionis Pharmaceuticals, Inc. (IONS) News
Filter IONS News Items
IONS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IONS News Highlights
- IONS's 30 day story count now stands at 9.
- Over the past 17 days, the trend for IONS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- DRUG, GENE and HAE are the most mentioned tickers in articles about IONS.
Latest IONS News From Around the Web
Below are the latest news stories about IONIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate IONS as an investment opportunity.
3 Stocks to Buy Now Before They Become Tomorrow’s Trillion-Dollar CompaniesThese future trillion dollar stocks can solidify portfolio growth for long-term investors. |
Ionis Pharmaceuticals Inc EVP, Chief Scientific Officer C Bennett Sells 22,613 SharesIonis Pharmaceuticals Inc (NASDAQ:IONS), a leader in RNA-targeted drug discovery and development, has experienced a recent insider sell according to a SEC Filing. |
WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosisIonis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved Ionis and AstraZeneca's WAINUA™ (eplontersen) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN. WAINUA is the only approved medicine for the treatment of ATTRv-PN that can be self-administered via an auto-injector. |
CORRECTED-UPDATE 2-US FDA approves Ionis-AstraZeneca's nerve disease drugThe U.S. Food and Drug Administration (FDA) on Thursday approved Ionis Pharmaceuticals and partner AstraZeneca's drug to treat nerve damage caused by a life-shortening rare disease. The drug, branded as Wainua, is approved for patients with polyneuropathy, or nerve damage caused by hereditary transthyretin amyloidosis (ATTR-PN), which affects an estimated 40,000 patients globally. Transthyretin amyloidosis is a progressive condition characterized by the build-up of abnormal protein deposits in the body's organs and tissues. |
12 Most Promising Gene Editing Stocks According to Hedge FundsIn this piece, we will take a look at the 12 most promising gene editing stocks according to hedge funds. If you want to skip our take on how the gene editing industry sits right at the top of the global innovation food chain, then you can take a look at the 5 Most Promising […] |
Ionis to present at 42nd Annual J.P. Morgan Healthcare ConferenceIonis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Wednesday, January 10, 2024. |
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to OtsukaPer the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe. |
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedemaIonis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen, an investigational prophylactic treatment for hereditary angioedema (HAE). Ionis will maintain responsibility for the non-clinical and clinical development of donidalorsen, and Otsuka will be responsible for European regulatory filings and commercialization. |
Ionis announces the appointment of Michael Yang to Board of DirectorsIonis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors. Mr. Yang's appointment expands the total number of Ionis Board members to 10. |
Why Is Sage Therapeutics, Inc. (SAGE) Up 12.7% Since Last Earnings Report?Sage Therapeutics, Inc. (SAGE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |